Observe Medical ASA - New CEO appointed


Observe Medical ASA - New CEO appointed and board authorisation approved
Observe Medical ASA: New CEO appointed and board authorisation to increase the share capital of the company proposed by the board and approved by the extraordinary general meeting.

Oslo, 24 October 2019: Observe Medical ASA (the "Company") today announces that Björn Larsson is appointed Chief Executive Officer of the Company effective mid-December 2019. Mr. Larsson succeeds Ole Henrik Eriksen who has held the position as interim CEO of the Company in connection with its listing process.

Björn Larsson is an experienced marketing and business development professional, who has held various senior positions within medical technology, pharmaceuticals and biotechnology. Previous experience includes Dentsply (previously Astra Tech), Medtronic, Mentice AstraZeneca and Novo Nordisk. Björn has comprehensive experience from commercialization of life science start-ups, in both operational roles and board positions. He comes from the position as Director, Corporate Communications at ABIGO Medical, a Swedish pharmaceutical and medtech company. He is also Chairman of the Board at Alzinova, a Swedish biotech company, developing a vaccine for the treatment of Alzheimer’s disease, which is listed on Nasdaq First North in Stockholm. Björn Larsson holds an MSc in Engineering from Chalmers University of Technology, Gothenburg, Sweden.

“We are pleased to announce that Björn Larsson has been appointed CEO of Observe Medical ASA. Björn has extensive experience from senior positions within medical technology and in commercialization of innovative healthcare products and solutions. We are looking forward to working together with Björn in executing on the company’s growth and development plan,” says Terje Bakken, Chairman of the Board of Observe Medical ASA.

Björn Larsson will assume his new position in mid-December 2019, and at such time Ole Henrik Eriksen will step down from his position as interim CEO and will no longer have any positions with the Company or its subsidiaries.

As part of Mr. Larsson's remuneration package he will receive 120,000 share options in the Company upon commencement of his position with the Company.

Furthermore, at a board meeting of the Company held today, the board of directors proposed that an authorisation is given to the board of directors to increase the Company's share capital by up to NOK 200,000. The authorisation is conditional upon the completion of the demerger of Navamedic ASA as set out in the demerger plan dated 19 June 2019. The shares to be issued under the board authorisation may be used by the Company's board of directors to honour the options transferred to the Company in connection with the demerger and other options to be issued under the Company's long-term incentive program or otherwise. The extraordinary general meeting of the Company resolved in a meeting held today to give the authorisation as proposed by the board of directors. The minutes of the extraordinary general meeting is attached hereto.


For further information, please contact:

Ole Henrik Eriksen, interim CEO
Mobile: +47 400 62 000
E-mail: ole.henrik.eriksen@navamedic.com
navas
25.10.2019 kl 01:22 343

Kan virke som et bra valg av ny CEO dette, lang og bred bransjeerfaring har han definitivt. Så får tiden vise om han fortjener opsjonen på 120 000 aksjer som han får tildelt allerede ved sin inntreden medio desember.
inva
30.10.2019 kl 15:59 191

Oslo Børs vedtok å ta aksjene i Observe Medical ASA opp til notering på Oslo Axess. Det forutsettes at selskapet før første noteringsdag oppfyller opptakskravene på Oslo Axess. Børsdirektøren fastsetter første noteringsdag, senest 13. desember 2019.